PMC:7464116 / 82245-82958
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T431 | 493-497 | Body_part | denotes | mRNA | http://purl.org/sig/ont/fma/fma67122 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T771 | 0-8 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T772 | 117-125 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T773 | 361-369 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T774 | 517-520 | Disease | denotes | Ad5 | http://purl.obolibrary.org/obo/MONDO_0011194 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T930 | 256-257 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T931 | 285-288 | http://purl.obolibrary.org/obo/CLO_0001079 | denotes | 148 |
| T932 | 379-382 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T96197 | 577-579 | Chemical | denotes | LV | http://purl.obolibrary.org/obo/CHEBI_73579 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T493 | 0-112 | Sentence | denotes | COVID-19 treatment is essentially supportive and, in fact, specific vaccines or therapies are not yet available. |
| T494 | 113-189 | Sentence | denotes | The COVID-19 vaccine is considered to be an effective prophylactic strategy. |
| T495 | 190-290 | Sentence | denotes | About 90 institutions around the world are working on identifying a specific and safe vaccine [148]. |
| T496 | 291-415 | Sentence | denotes | As of 8 April 2020, the global research and development landscape for COVID-19 vaccines has included 115 vaccine candidates. |
| T497 | 416-713 | Sentence | denotes | Most of these are currently in the preclinical phase and only some of these (mRNA-1273 from Moderna, Ad5-nCoV from CanSino Biologicals, INO-4800 from Inovio and LV-SMENP-DC and pathogen-specific aAPC from Shenzhen Geno-Immune Medical Institute) have recently moved into clinical development [149]. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2451 | 517-520 | Gene | denotes | Ad5 | Gene:8081 |
| 2452 | 521-525 | Species | denotes | nCoV | Tax:2697049 |
| 2453 | 0-8 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 2454 | 117-125 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 2455 | 361-369 | Disease | denotes | COVID-19 | MESH:C000657245 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32759645-32347054-58096284 | 285-288 | 32347054 | denotes | 148 |
| 32759645-32273591-58096285 | 708-711 | 32273591 | denotes | 149 |